Rossignol, Patrick
David, Lea
Chan, Christine
Conrad, Ansgar
Weir, Matthew R.
Funding for this research was provided by:
Vifor Pharma
Article History
Accepted: 22 April 2021
First Online: 20 May 2021
Declarations
:
: The analysis reported in this manuscript were funded by Vifor Pharma, Inc.
: Patrick Rossignol has consulted for Bayer, G3P, Idorsia, and KBP; has received honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Corvidia, CVRx, Fresenius, Grunenthal, Novartis, Novo Nordisk, Vifor Pharma, Inc., Sanofi, Sequana Medical, Servier, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma; and is a cofounder of CardioRenal. Lea David, Christine Chan, and Ansgar Conrad are employed by and own stock in Vifor Pharma, Inc. Matthew R. Weir has consulted for and received honoraria for scientific advisory boards from Vifor Pharma, Inc., Vifor Pharma Management Ltd., AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, MSD, and Novo Nordisk.
: The datasets generated and analyzed for this study are from the global pharmacovigilance database of Vifor Pharma, Inc. and are not publicly available. Patiromer postmarketing reports are submitted to the FDA and can be obtained via the FDA Adverse Event Reporting System (FAERS), a public database that contains information on AEs and medication error reports submitted to the FDA.
: All studies included in this analysis were conducted in accordance with the ethical principles that comply with the Declaration of Helsinki and are consistent with good clinical practices and applicable regulatory requirements.
: Not applicable.
: All authors contributed to the conception and design of the analysis as well as the interpretation of data and critical review of this manuscript. All authors approved the manuscript for submission to the journal. The authors assume responsibility and accountability for data integrity and accuracy.